Want to see AXSM full AI Analyst Report?

Axsome Therapeutics (AXSM) Price & Analysis

2,405 Followers

AXSM Stock Chart & Stats

$205.48

-$0.53(-0.22%)

At close: Jul 24 4:00 PM EDT

$205.48

-$0.53(-0.22%)

Day’s Range― - ―

52-Week Range$117.30 - $260.19

Previous CloseN/A

Volume461.99K

Average Volume (3M)632.19K

Market Cap

$9.54B

Enterprise Value$12.58K

Total Cash (Recent Filing)$319.85M

Total Debt (Recent Filing)$219.21M

Price to Earnings (P/E)―

Beta0.85

Next Earnings

Nov 09, 2026

EPS Estimate

-0.51

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-3.75

Shares Outstanding52,380,817

10 Day Avg. Volume782,896

30 Day Avg. Volume632,190

Financial Highlights & Ratios

PEG Ratio1.29

Price to Book (P/B)102.90

Price to Sales (P/S)14.23

P/FCF Ratio-96.78

Enterprise Value/Market Cap<0.01

Enterprise Value/Revenue<0.01

Enterprise Value/Gross Profit<0.01

Enterprise Value/Ebitda>-0.01

Forecast

1Y Price Target

$288.57

Price Target Upside40.44% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering15

EPS Forecast (FY)-2.7

Revenue Forecast (FY)$962.48M

Bulls Say, Bears Say

Bulls Say

Revenue Scaling And Gross MarginRapid revenue expansion alongside an approximately 93% gross margin shows that Axsome is building meaningful commercial scale in its marketed CNS portfolio. If growth continues, the high gross-profit contribution can provide substantial operating leverage as launch investments moderate and products mature.

Growing Product Demand And AccessAUVELITY is gaining prescriptions faster than the broader antidepressant market, while payer coverage and prescriber reach continue to expand. This combination of demand outperformance and improving access supports durable market penetration and gives the commercial organization a stronger base for future growth.

Late-Stage CNS PipelineRegulatory progress for AXS-12 and a broad neuroscience pipeline create multiple opportunities to extend Axsome’s revenue base beyond current products. The potential to file, on average, one NDA annually through 2030 provides a durable product-renewal strategy if clinical and regulatory milestones are achieved.

Bears Say

Persistent Operating LossesDespite strong revenue growth and gross margins, Axsome remains materially unprofitable at both the operating and net-income levels. Continued losses reduce internally generated capital for commercialization and pipeline development, leaving execution dependent on achieving further scale and converting gross profit into sustainable earnings.

Negative Cash GenerationThe company is still consuming cash to fund operations, so revenue growth has not yet translated into self-financing expansion. Although burn has narrowed from prior years, continued negative free cash flow can constrain investment flexibility and require reliance on existing liquidity or financing until operations turn positive.

High Leverage And Thin EquityDebt is large relative to the company’s equity base, increasing financial pressure while Axsome remains loss-making and cash-flow negative. This capital structure leaves less balance-sheet flexibility for setbacks or additional investment, and leverage will remain a constraint until profitability improves or equity expands.

Axsome Therapeutics News

Axsome Therapeutics price target lowered to $267 from $280 at Deutsche Bank

Deutsche Bank lowered the firm’s price target on Axsome Therapeutics (AXSM) to $267 from $280 and keeps a...

5d ago

AXSM

Axsome Therapeutics price target lowered to $247 from $251 at Morgan Stanley

Morgan Stanley lowered the firm’s price target on Axsome Therapeutics (AXSM) to $247 from $251 and keeps an...

9d ago

AXSM

Axsome Therapeutics assumed with a Buy at Truist

Truist assumed coverage of Axsome Therapeutics (AXSM) with a Buy rating with a price target of $285, up...

11d ago

AXSM

Axsome rises as Mizuho highlights ‘big month-over-month jump’ for Auvelity

Mizuho analyst Graig Suvannavejh reports Bloomberg Symphony prescription data for the 30mg titration dose for Auvelity in ADA...

23d ago

AXSM

Axsome pullback brings attractive entry point, says H.C. Wainwright

H.C. Wainwright keeps a Buy rating on Axsome Therapeutics (AXSM) with a $290 price target after the company...

1M ago

AXSM

Ram Selvaraju Reaffirms Buy on Axsome, Maintaining $290 Price Target Amid Solid Execution and AUVELITY Upside Potential

H.C. Wainwright analyst Ram Selvaraju has reiterated their bullish stance on AXSM stock, giving a Buy rating on...

1M ago

AXSM

Axsome Therapeutics price target raised to $316 from $306 at Mizuho

Mizuho analyst Graig Suvannavejh raised the firm’s price target on Axsome Therapeutics (AXSM) to $316 from $306 and...

2M ago

AXSM

Axsome Targets Smoking Cessation With New Phase 3 AXS-05 Trial

Axsome Therapeutics Inc. ($AXSM) announced an update on their ongoing clinical study. The study titled “A Randomized, Double-Blind,...

2M ago

AXSM

Axsome Therapeutics price target lowered to $297 from $304 at RBC Capital

RBC Capital analyst Leonid Timashev lowered the firm’s price target on Axsome Therapeutics (AXSM) to $297 from $304...

2M ago

AXSM

Analyst Reiterates Buy on Axsome, Sees Undervalued Pipeline Upside with Unchanged $310 Price Target

Malcolm Hoffman, an analyst from BMO Capital, maintained the Buy rating on Axsome Therapeutics. The associated price target...

2M ago

AXSM

Axsome Therapeutics price target raised to $251 from $242 at Morgan Stanley

Morgan Stanley raised the firm’s price target on Axsome Therapeutics (AXSM) to $251 from $242 and keeps an...

2M ago

AXSM

Axsome Therapeutics price target raised to $275 from $260 at Guggenheim

Guggenheim raised the firm’s price target on Axsome Therapeutics (AXSM) to $275 from $260 and keeps a Buy...

2M ago

AXSM

Axsome Therapeutics price target raised to $256 from $255 at Wells Fargo

Wells Fargo raised the firm’s price target on Axsome Therapeutics (AXSM) to $256 from $255 and keeps an...

2M ago

AXSM

Auvelity Momentum and Pipeline Progress Drive Undervalued Upside in Axsome, Supporting Buy Rating

Bank of America Securities analyst Jason Gerberry has reiterated their bullish stance on AXSM stock, giving a Buy...

2M ago

AXSM

AXSM FAQ

What was Axsome Therapeutics Inc’s price range in the past 12 months?

Axsome Therapeutics Inc lowest stock price was $117.30 and its highest was $260.19 in the past 12 months.

What is Axsome Therapeutics Inc’s market cap?

Axsome Therapeutics Inc’s market cap is $9.54B.

When is Axsome Therapeutics Inc’s upcoming earnings report date?

Axsome Therapeutics Inc’s upcoming earnings report date is Nov 09, 2026 which is in 36 days.

How were Axsome Therapeutics Inc’s earnings last quarter?

Axsome Therapeutics Inc released its earnings results on Aug 10, 2026. The company reported -$0.99 earnings per share for the quarter, missing the consensus estimate of -$0.892 by -$0.098.

Is Axsome Therapeutics Inc overvalued?

According to Wall Street analysts Axsome Therapeutics Inc’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Axsome Therapeutics Inc pay dividends?

Axsome Therapeutics Inc does not currently pay dividends.

What is Axsome Therapeutics Inc’s EPS estimate?

Axsome Therapeutics Inc’s EPS estimate is -0.51.

How many shares outstanding does Axsome Therapeutics Inc have?

Axsome Therapeutics Inc has 52,380,817 shares outstanding.

What happened to Axsome Therapeutics Inc’s price movement after its last earnings report?

Axsome Therapeutics Inc reported an EPS of -$0.99 in its last earnings report, missing expectations of -$0.892. Following the earnings report the stock price went up 3.831%.

Which hedge fund is a major shareholder of Axsome Therapeutics Inc?

Currently, no hedge funds are holding shares in AXSM

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Axsome Therapeutics Stock Smart Score

Outperform

Fundamentals

Return on Equity

―

Trailing 12-Months

Asset Growth

19.02%

Trailing 12-Months

Learn more about TipRanks Smart Score

Top Smart Score Stocks >

Company Description

Axsome Therapeutics Inc

Axsome Therapeutics, Inc. is a biopharmaceutical company dedicated to discovering and advancing innovative treatments for a range of central nervous system (CNS) disorders within the United States. Its robust product pipeline features several promising candidates, including: AXS-05, an investigational therapy currently being developed for major depressive disorder and treatment-resistant depression. This compound is also in Phase III clinical evaluation for Alzheimer's disease agitation and has successfully finished Phase II trials investigating its use for smoking cessation. AXS-07, a novel, orally administered, rapidly-acting investigational medicine that employs multiple mechanisms of action. It has concluded two Phase III studies for the acute treatment of migraine attacks. AXS-12, a selective and potent norepinephrine reuptake inhibitor, which is presently undergoing a Phase III trial for narcolepsy. AXS-14, an oral investigational drug, advancing through Phase III trials for the management of fibromyalgia. Axsome Therapeutics also engages in a research collaboration with Duke University to further assess AXS-05's potential in smoking cessation. The company, established in 2012, has its main offices in New York, New York.

Axsome Therapeutics (AXSM) Earnings & Revenues

Historic Earnings Reports

AXSM Company Deck

AXSM Earnings Call

Q2 2026

0:00 / 0:00

Earnings Call Sentiment|Positive

The call conveyed strong positive momentum across Axsome’s commercial portfolio, with 46% revenue growth, accelerating AUVELITY demand, encouraging early Alzheimer’s disease agitation launch metrics, continued SYMBRAVO and SUNOSI prescription growth, improving payer coverage, and substantial pipeline progress. The company remains loss-making, reported higher SG&A and ongoing cash burn, and acknowledged that several Alzheimer’s disease agitation launch metrics are still early and limited. Overall, the highlights significantly outweighed the lowlights.View all AXSM earnings summaries

AXSM Stock 12 Month Forecast

Average Price Target

$288.57

▲(40.44% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"117":"$117","183":"$183","249":"$249","315":"$315","381":"$381"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":380,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$380.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":288.57142857142856,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$288.57</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":247,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$247.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[117,183,249,315,381],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2026","6":"Apr<br/>2026","9":"Jul<br/>2026","12":"Oct<br/>2026","25":"Oct<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,182.07,197.29538461538462,212.52076923076922,227.74615384615385,242.97153846153844,258.1969230769231,273.4223076923077,288.6476923076923,303.87307692307695,319.09846153846155,334.32384615384615,349.5492307692308,364.7746153846154,{"y":380,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,182.07,190.26241758241758,198.45483516483515,206.64725274725274,214.83967032967033,223.0320879120879,231.22450549450548,239.41692307692307,247.60934065934066,255.80175824175822,263.99417582417584,272.1865934065934,280.37901098901096,{"y":288.57142857142856,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,182.07,187.06461538461537,192.05923076923077,197.05384615384614,202.04846153846154,207.0430769230769,212.0376923076923,217.03230769230768,222.02692307692308,227.02153846153846,232.01615384615386,237.01076923076923,242.00538461538463,{"y":247,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":118.57,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":134.99,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":149.03,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":182.64,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 42,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":185.88,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 43,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":166.38,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 41,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":171.78,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":206.53,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 38,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":230.25,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 39,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":240.66,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":217.99,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":202.83,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":182.07,"date":1790812800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >